Latest Breaking News On - Amended annual report - Page 1 : comparemela.com

Virios Therapeutics Announces Closing of $1 7 Million

Virios Therapeutics Announces Closing of $1 7 Million
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMaxim groupVirios therapeutics incCompany or virios therapeuticsExchange commissionProspectus departmentVirios therapeuticsSecurities litigation reform actVirios therapeuticAmended annual report

Virios Therapeutics Announces Pricing of $1 7 Million Public Offering of Common Stock to

ATLANTA, May 19, 2024 (GLOBE NEWSWIRE) Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating

New yorkUnited statesCompany or virios therapeuticsVirios therapeutics incExchange commissionMaxim groupProspectus departmentVirios therapeuticsSecurities litigation reform actVirios therapeuticAmended annual report

Virios Therapeutics Announces Pricing of $1 7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

ATLANTA, May 19, 2024 Virios Therapeutics, Inc. , a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including.

New yorkUnited statesProspectus departmentGlobenewswire incCompany or virios therapeuticsMaxim groupExchange commissionVirios therapeutics incSecurities litigation reform actVirios therapeuticAmended annual report

Virios Therapeutics Announces Pricing of $1 7 Million

Virios Therapeutics Announces Pricing of $1 7 Million
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesCompany or virios therapeuticsExchange commissionVirios therapeutics incMaxim groupProspectus departmentVirios therapeuticsSecurities litigation reform actVirios therapeuticAmended annual report

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesVirios therapeutics incGlobenewswire incMaxim groupCompany or virios therapeuticsExchange commissionProspectus departmentSecurities litigation reform actVirios therapeuticAmended annual report